{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:36:00Z","timestamp":1790876160636,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,19]]},"DOI":"10.7759\/cureus.22393","type":"journal-article","created":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T03:27:31Z","timestamp":1645327651000},"source":"Crossref","is-referenced-by-count":9,"title":["New Trends in the Diagnosis and Management of Hypertension"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Tinawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018, 71:e13-e115. 10.1161\/HYP.0000000000000065","journal-title":"Hypertension"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020, 181:271-280.e8. 10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32834f04b6","article-title":"Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications","volume":"30","author":"Soro-Paavonen A","year":"2012","unstructured":"Soro-Paavonen A, Gordin D, Forsblom C, et al.. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens. 2012, 30:375-83. 10.1097\/HJH.0b013e32834f04b6","journal-title":"J Hypertens"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19","volume":"382","author":"Vaduganathan M","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020, 382:1653-9. 10.1056\/NEJMsr2005760","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of COVID-19","volume":"382","author":"Mancia G","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020, 382:2431-40. 10.1056\/NEJMoa2006923","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.34067\/kid.0003792020","article-title":"Outcomes associated with the use of renin-angiotensin-aldosterone system blockade in hospitalized patients with SARS-CoV-2 infection","volume":"1","author":"Chaudhri I","year":"2020","unstructured":"Chaudhri I, Koraishy FM, Bolotova O, et al.. Outcomes associated with the use of renin-angiotensin-aldosterone system blockade in hospitalized patients with SARS-CoV-2 infection. Kidney360. 2020, 1:801-9. 10.34067\/kid.0003792020","journal-title":"Kidney360"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1681\/nsap.2020.19.1.1","article-title":"Hypertension in the time of the COVID-19 pandemic: new issues and enduring controversies","volume":"19","author":"Oparil S","year":"2020","unstructured":"Oparil S. Hypertension in the time of the COVID-19 pandemic: new issues and enduring controversies . Nephrology Self-Assessment Program. 2020, 19:1-7. 10.1681\/nsap.2020.19.1.1","journal-title":"Nephrology Self-Assessment Program"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3594","article-title":"Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"Baral R","year":"2021","unstructured":"Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, Vassiliou VS. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Netw Open. 2021, 4:e213594. 10.1001\/jamanetworkopen.2021.3594","journal-title":"JAMA Netw Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032582","article-title":"Potential US population impact of the 2017 ACC\/AHA high blood pressure guideline","volume":"137","author":"Muntner P","year":"2018","unstructured":"Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK. Potential US population impact of the 2017 ACC\/AHA high blood pressure guideline. Circulation. 2018, 137:109-18. 10.1161\/CIRCULATIONAHA.117.032582","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger T","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al.. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020, 75:1334-57. 10.1161\/HYPERTENSIONAHA.120.15026","journal-title":"Hypertension"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","unstructured":"KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021, 99.S1-S87. 10.1016\/j.kint.2020.11.003","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.26502\/fccm.92920239","article-title":"Current trends in hypertension: takeaways from the 2021 KDIGO guidelines for the management of blood pressure in chronic kidney disease","volume":"6","author":"Tinawi M","year":"2022","unstructured":"Tinawi M. Current trends in hypertension: takeaways from the 2021 KDIGO guidelines for the management of blood pressure in chronic kidney disease. Cardiology and Cardiovascular Medicine. 2022, 6:7-12.","journal-title":"Cardiology and Cardiovascular Medicine"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group","volume":"330","author":"Klahr S","year":"1994","unstructured":"Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med. 1994, 330:877-84. 10.1056\/NEJM199403313301301","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright JT Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T, et al.. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002, 288:2421-31. 10.1001\/jama.288.19.2421","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN- 2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti P","year":"2005","unstructured":"Ruggenenti P, Perna A, Loriga G, et al.. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN- 2): multicentre, randomised controlled trial. Lancet. 2005, 365:939-46. 10.1016\/S0140-6736(05)71082-5","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman WC","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, et al.. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010, 362:1575-85. 10.1056\/NEJMoa1001286","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright JT Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, et al.. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015, 373:2103-16. 10.1056\/NEJMoa1511939","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung AK","year":"2017","unstructured":"Cheung AK, Rahman M, Reboussin DM, et al.. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017, 28:2812-23. 10.1681\/ASN.2017020148","journal-title":"J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018121261","article-title":"Implications of early decline in eGFR due to intensive bp control for cardiovascular outcomes in SPRINT","volume":"30","author":"Beddhu S","year":"2019","unstructured":"Beddhu S, Shen J, Cheung AK, et al.. Implications of early decline in eGFR due to intensive bp control for cardiovascular outcomes in SPRINT. J Am Soc Nephrol. 2019, 30:1523-33. 10.1681\/ASN.2018121261","journal-title":"J Am Soc Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial","volume":"321","author":"Williamson JD","year":"2019","unstructured":"Williamson JD, Pajewski NM, Auchus AP, et al.. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019, 321:553-61. 10.1001\/jama.2018.21442","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"Lewis CE","year":"2021","unstructured":"Lewis CE, Fine LJ, Beddhu S, et al.. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021, 384:1921-30. 10.1056\/NEJMoa1901281","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang W","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, et al.. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021, 385:1268-79. 10.1056\/NEJMoa2111437","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1539","article-title":"Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force","volume":"162","author":"Piper MA","year":"2015","unstructured":"Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015, 162:192-204. 10.7326\/M14-1539","journal-title":"Ann Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey RM","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, et al.. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018, 72:e53-90. 10.1161\/HYP.0000000000000084","journal-title":"Hypertension"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal R","year":"2021","unstructured":"Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, Tu W. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021, 385:2507-19. 10.1056\/NEJMoa2110730","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder JW","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, et al.. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016, 101:1889-916. 10.1210\/jc.2015-4061","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown JM","year":"2020","unstructured":"Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020, 173:10-20. 10.7326\/M20-0065","journal-title":"Ann Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118235","article-title":"Sympathetic neural mechanisms in obstructive sleep apnea","volume":"96","author":"Somers VK","year":"1995","unstructured":"Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995, 96:1897-904. 10.1172\/JCI118235","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11180","article-title":"Renal denervation in resistant hypertension and obstructive sleep apnea: randomized proof-of-concept phase ii trial","volume":"72","author":"Warchol-Celinska E","year":"2018","unstructured":"Warchol-Celinska E, Prejbisz A, Kadziela J, et al.. Renal denervation in resistant hypertension and obstructive sleep apnea: randomized proof-of-concept phase ii trial. Hypertension. 2018, 72:381-90. 10.1161\/HYPERTENSIONAHA.118.11180","journal-title":"Hypertension"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: mechanistic links","volume":"15","author":"Hall JE","year":"2019","unstructured":"Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019, 15:367-85. 10.1038\/s41581-019-0145-4","journal-title":"Nat Rev Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1530\/JME-16-0025","article-title":"Adipocytes, aldosterone and obesity-related hypertension","volume":"57","author":"Dinh Cat AN","year":"2016","unstructured":"Dinh Cat AN, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016, 57:F7-F21. 10.1530\/JME-16-0025","journal-title":"J Mol Endocrinol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpw105","article-title":"Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension","volume":"30","author":"Dudenbostel T","year":"2017","unstructured":"Dudenbostel T, Calhoun DA. Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. Am J Hypertens. 2017, 30:103-9. 10.1093\/ajh\/hpw105","journal-title":"Am J Hypertens"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20160141","article-title":"Adipokines are associated with hypertension in metabolically healthy obese (mho) children and adolescents: a prospective population-based cohort study","volume":"28","author":"Ding W","year":"2018","unstructured":"Ding W, Cheng H, Chen F, et al.. Adipokines are associated with hypertension in metabolically healthy obese (mho) children and adolescents: a prospective population-based cohort study. J Epidemiol. 2018, 28:19-26. 10.2188\/jea.JE20160141","journal-title":"J Epidemiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3781","article-title":"Three-year outcomes of bariatric surgery in patients with obesity and hypertension: a randomized clinical trial","volume":"173","author":"Schiavon CA","year":"2020","unstructured":"Schiavon CA, Bhatt DL, Ikeoka D, et al.. Three-year outcomes of bariatric surgery in patients with obesity and hypertension: a randomized clinical trial. Ann Intern Med. 2020, 173:685-93. 10.7326\/M19-3781","journal-title":"Ann Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.21402","article-title":"Association of isolated diastolic hypertension as defined by the 2017 ACC\/AHA blood pressure guideline with incident cardiovascular outcomes","volume":"323","author":"McEvoy JW","year":"2020","unstructured":"McEvoy JW, Daya N, Rahman F, et al.. Association of isolated diastolic hypertension as defined by the 2017 ACC\/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA. 2020, 323:329-38. 10.1001\/jama.2019.21402","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"Flint AC","year":"2019","unstructured":"Flint AC, Conell C, Ren X, et al.. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019, 381:243-51. 10.1056\/NEJMoa1803180","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1613481","article-title":"Initial treatment of hypertension","volume":"378","author":"Taler SJ","year":"2018","unstructured":"Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018, 378:636-44. 10.1056\/NEJMcp1613481","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.26502\/aimr.0025","article-title":"Hyponatremia and hypernatremia: a practical guide to disorders of water balance","volume":"3","author":"Tinawi M","year":"2020","unstructured":"Tinawi M. Hyponatremia and hypernatremia: a practical guide to disorders of water balance. Arch Intern Med Res. 2020, 3:74-95. 10.26502\/aimr.0025","journal-title":"Arch Intern Med Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","unstructured":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288:2981-97. 10.1001\/jama.288.23.2981","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105675","article-title":"Effect of salt substitution on cardiovascular events and death","volume":"385","author":"Neal B","year":"2021","unstructured":"Neal B, Wu Y, Feng X, et al.. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021, 385:1067-77. 10.1056\/NEJMoa2105675","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/85991-new-trends-in-the-diagnosis-and-management-of-hypertension","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:02Z","timestamp":1707507962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/85991-new-trends-in-the-diagnosis-and-management-of-hypertension"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.22393","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,19]]}}}